S&P 500   3,120.54 (+0.00%)
DOW   28,014.84 (+0.04%)
QQQ   202.77 (-0.07%)
CGC   14.52 (-5.28%)
BABA   186.13 (+0.35%)
GE   11.35 (-1.48%)
T   39.49 (-0.03%)
ACB   2.34 (-14.29%)
F   8.97 (+0.22%)
BAC   32.94 (+0.03%)
DIS   148.20 (+2.44%)
S&P 500   3,120.54 (+0.00%)
DOW   28,014.84 (+0.04%)
QQQ   202.77 (-0.07%)
CGC   14.52 (-5.28%)
BABA   186.13 (+0.35%)
GE   11.35 (-1.48%)
T   39.49 (-0.03%)
ACB   2.34 (-14.29%)
F   8.97 (+0.22%)
BAC   32.94 (+0.03%)
DIS   148.20 (+2.44%)
S&P 500   3,120.54 (+0.00%)
DOW   28,014.84 (+0.04%)
QQQ   202.77 (-0.07%)
CGC   14.52 (-5.28%)
BABA   186.13 (+0.35%)
GE   11.35 (-1.48%)
T   39.49 (-0.03%)
ACB   2.34 (-14.29%)
F   8.97 (+0.22%)
BAC   32.94 (+0.03%)
DIS   148.20 (+2.44%)
S&P 500   3,120.54 (+0.00%)
DOW   28,014.84 (+0.04%)
QQQ   202.77 (-0.07%)
CGC   14.52 (-5.28%)
BABA   186.13 (+0.35%)
GE   11.35 (-1.48%)
T   39.49 (-0.03%)
ACB   2.34 (-14.29%)
F   8.97 (+0.22%)
BAC   32.94 (+0.03%)
DIS   148.20 (+2.44%)
Log in

Kura Oncology Stock Price, Forecast & Analysis (NASDAQ:KURA)

$14.51
-0.20 (-1.36 %)
(As of 11/18/2019 12:19 PM ET)
Today's Range
$14.49
Now: $14.51
$14.81
50-Day Range
$12.79
MA: $14.79
$15.61
52-Week Range
$11.01
Now: $14.51
$21.42
Volume1,910 shs
Average Volume237,078 shs
Market Capitalization$657.45 million
P/E RatioN/A
Dividend YieldN/A
Beta2.57
Kura Oncology, Inc, a clinical-stage biopharmaceutical company, develops medicines for the treatment of cancer. Its pipeline consists of small molecule product candidates that target cancer. The company's lead product candidate is Tipifarnib, an oral farnesyl transferase inhibitor that is in Phase II clinical trials for the treatment of solid tumors, peripheral T-cell lymphomas, myelodysplastic syndromes, acute myeloid leukemia, and chronic myelomonocytic leukemia. Read More…

Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:KURA
CUSIPN/A
Phone858-500-8800

Debt

Price-To-Earnings

Sales & Book Value

Annual SalesN/A
Book Value$5.15 per share

Profitability

Net Income$-60,450,000.00

Miscellaneous

Employees43
Market Cap$657.45 million
Next Earnings Date3/3/2020 (Estimated)
OptionableOptionable

Receive KURA News and Ratings via Email

Sign-up to receive the latest news and ratings for KURA and its competitors with MarketBeat's FREE daily newsletter.


Kura Oncology (NASDAQ:KURA) Frequently Asked Questions

What is Kura Oncology's stock symbol?

Kura Oncology trades on the NASDAQ under the ticker symbol "KURA."

How were Kura Oncology's earnings last quarter?

Kura Oncology Inc (NASDAQ:KURA) issued its earnings results on Tuesday, November, 5th. The company reported ($0.36) earnings per share for the quarter, topping the Zacks' consensus estimate of ($0.39) by $0.03. View Kura Oncology's Earnings History.

When is Kura Oncology's next earnings date?

Kura Oncology is scheduled to release their next quarterly earnings announcement on Tuesday, March 3rd 2020. View Earnings Estimates for Kura Oncology.

What price target have analysts set for KURA?

9 equities research analysts have issued 1 year target prices for Kura Oncology's shares. Their forecasts range from $22.00 to $32.00. On average, they anticipate Kura Oncology's share price to reach $27.25 in the next year. This suggests a possible upside of 87.8% from the stock's current price. View Analyst Price Targets for Kura Oncology.

What is the consensus analysts' recommendation for Kura Oncology?

9 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Kura Oncology in the last year. There are currently 9 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Kura Oncology.

Has Kura Oncology been receiving favorable news coverage?

News stories about KURA stock have trended very negative recently, InfoTrie Sentiment Analysis reports. InfoTrie scores the sentiment of news coverage by analyzing more than six thousand news and blog sources. The firm ranks coverage of public companies on a scale of negative five to positive five, with scores nearest to five being the most favorable. Kura Oncology earned a news sentiment score of -3.0 on InfoTrie's scale. They also gave news stories about the company a news buzz of 10.0 out of 10, meaning that recent news coverage is extremely likely to have an effect on the company's share price in the near term. View News Stories for Kura Oncology.

Are investors shorting Kura Oncology?

Kura Oncology saw a drop in short interest in the month of October. As of October 15th, there was short interest totalling 2,460,000 shares, a drop of 6.5% from the September 15th total of 2,630,000 shares. Based on an average trading volume of 248,400 shares, the days-to-cover ratio is currently 9.9 days. Currently, 6.2% of the shares of the company are sold short. View Kura Oncology's Current Options Chain.

Who are some of Kura Oncology's key competitors?

What other stocks do shareholders of Kura Oncology own?

Who are Kura Oncology's key executives?

Kura Oncology's management team includes the folowing people:
  • Dr. Troy Edward Wilson, Chairman, CEO & Pres (Age 50)
  • Dr. Antonio Gualberto, Head of Devel. & Chief Medical Officer (Age 54)
  • Dr. Marc Grasso, CFO & Chief Bus. Officer
  • Mr. John Farnam, Chief Operating Officer
  • Mr. Pete De Spain, VP of Investor Relations & Corp. Communications

Who are Kura Oncology's major shareholders?

Kura Oncology's stock is owned by many different of retail and institutional investors. Top institutional investors include Eagle Asset Management Inc. (4.59%), SG Americas Securities LLC (0.23%), Alps Advisors Inc. (0.20%), California Public Employees Retirement System (0.10%), Rhumbline Advisers (0.09%) and Bailard Inc. (0.08%). Company insiders that own Kura Oncology stock include Antonio Gualberto and Ecor1 Capital Fund Qualified,. View Institutional Ownership Trends for Kura Oncology.

Which institutional investors are selling Kura Oncology stock?

KURA stock was sold by a variety of institutional investors in the last quarter, including Tower Research Capital LLC TRC , Bailard Inc. and Pillar Pacific Capital Management LLC. View Insider Buying and Selling for Kura Oncology.

Which institutional investors are buying Kura Oncology stock?

KURA stock was acquired by a variety of institutional investors in the last quarter, including SG Americas Securities LLC, Eagle Asset Management Inc., California Public Employees Retirement System, Alps Advisors Inc., Russell Investments Group Ltd., Rhumbline Advisers, Meeder Asset Management Inc. and Zurcher Kantonalbank Zurich Cantonalbank. View Insider Buying and Selling for Kura Oncology.

How do I buy shares of Kura Oncology?

Shares of KURA can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

What is Kura Oncology's stock price today?

One share of KURA stock can currently be purchased for approximately $14.51.

How big of a company is Kura Oncology?

Kura Oncology has a market capitalization of $657.45 million. The company earns $-60,450,000.00 in net income (profit) each year or ($1.72) on an earnings per share basis. Kura Oncology employs 43 workers across the globe.View Additional Information About Kura Oncology.

What is Kura Oncology's official website?

The official website for Kura Oncology is http://www.kuraoncology.com/.

How can I contact Kura Oncology?

Kura Oncology's mailing address is 3033 SCIENCE PARK ROAD SUITE 220, SAN DIEGO CA, 92121. The company can be reached via phone at 858-500-8800 or via email at [email protected]


MarketBeat Community Rating for Kura Oncology (NASDAQ KURA)

Community Ranking:  2.7 out of 5 (star star)
Outperform Votes:  306 (Vote Outperform)
Underperform Votes:  258 (Vote Underperform)
Total Votes:  564
MarketBeat's community ratings are surveys of what our community members think about Kura Oncology and other stocks. Vote "Outperform" if you believe KURA will outperform the S&P 500 over the long term. Vote "Underperform" if you believe KURA will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 11/18/2019 by MarketBeat.com Staff

Featured Article: G-20

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel